-transparent.png){kind=logo}
Dipyridamole, previously reported to be an interferon (IFN) inducer in mice, was evaluated in 43 normal volunteers or cancer patients. At doses ranging from 150 mg orally to 887 mg intravenously, no serum antiviral activity suggesting IFN induction was observed.
Related Publications
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
October 1985,
Biochemistry international,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
May 1981,
Prostaglandins,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
April 1983,
The British journal of radiology,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
January 1984,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
May 1982,
Acta virologica,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
August 1984,
Lancet (London, England),
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
January 1981,
European journal of clinical pharmacology,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
April 1966,
Science (New York, N.Y.),
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
July 1983,
Acta virologica,
K A Havlin, and
A D Inglot, and
J K Willson, and
E C Borden, and
S Grossberg, and
B Szulc, and
A Gladysz, and
B Groehlich
August 1994,
Human reproduction (Oxford, England),
